Year All2024202320222021202020192018201720162015201420132012201120102007 11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias - Company expects to report initial clinical data in 2020 - WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced Read More 10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial Read More 08.28.19 Syndax Announces Participation at Four Upcoming Investor Conferences WALTHAM, Mass. , Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in four Read More 08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update - IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant acute leukemias - - Final interim OS analysis for E2112 expected in 4Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. , Aug. Read More 08.05.19 Syndax to Participate in the BTIG Biotechnology Conference WALTHAM, Mass. , Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019 WALTHAM, Mass. , July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial Read More 07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias -- SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein -- -- Strong tumor growth inhibition and improved survival observed in preclinical models -- WALTHAM, Mass. , July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Read More 06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More 05.14.19 Syndax to Present at the UBS Global Healthcare Conference WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More 04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 WALTHAM, Mass. , April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial Read More 04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit observed in biomarker-defined Read More
11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias - Company expects to report initial clinical data in 2020 - WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced Read More
10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial Read More
08.28.19 Syndax Announces Participation at Four Upcoming Investor Conferences WALTHAM, Mass. , Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in four Read More
08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update - IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant acute leukemias - - Final interim OS analysis for E2112 expected in 4Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. , Aug. Read More
08.05.19 Syndax to Participate in the BTIG Biotechnology Conference WALTHAM, Mass. , Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019 WALTHAM, Mass. , July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial Read More
07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias -- SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein -- -- Strong tumor growth inhibition and improved survival observed in preclinical models -- WALTHAM, Mass. , July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Read More
06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Read More
05.14.19 Syndax to Present at the UBS Global Healthcare Conference WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Read More
04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 WALTHAM, Mass. , April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial Read More
04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit observed in biomarker-defined Read More